Alx Oncology (ALXO)CEO sold ~$2.5K

~$2.5K

Approx. value · 2,159 sh @ $1.15

170K

Holds after · shares reported

Traded

Feb 19, 2025

Filed

Feb 21, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 30, 2024Insider · 2 peopleInsiders: 2 sales (~$19K)
2. Jan 6, 2025InsiderCFO sold ~$4K of ALXO shares in the open market
3. Feb 19, 2025 · this disclosureInsiderCEO sold ~$2.5K of ALXO shares in the open market

What came next

1. Feb 19, 2025Insider · 2 peopleInsiders: 2 sales (~$2K)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alx Oncology

For Alx Oncology, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALXO page.

Other recent filings by Jason Lettmann, CHIEF EXECUTIVE OFFICER

• SEC Form 4 at Alx Oncology (ALXO)Aug 18, 2026
• SEC Form 4 at Alx Oncology (ALXO)Mar 23, 2026
• SEC Form 4 at Alx Oncology (ALXO)Sep 18, 2025
• SEC Form 4 at Alx Oncology (ALXO)Sep 18, 2025
• SEC Form 4 at Alx Oncology (ALXO)Aug 19, 2025

The full history of Jason Lettmann, CHIEF EXECUTIVE OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Alx Oncology

• SEC Form 4Aug 18, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 4Jul 6, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Mar 23, 2026
• SEC Form 4Mar 23, 2026

Everything OQRO holds on this company is on its ALXO page.